[et_pb_section fb_built=\u00bb1″ _builder_version=\u00bb4.15″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_row _builder_version=\u00bb4.15.1″ _module_preset=\u00bbdefault\u00bb min_height=\u00bb454px\u00bb custom_margin=\u00bb|auto|-350px|auto||\u00bb custom_padding=\u00bb||0px|||\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb4_4″ _builder_version=\u00bb4.15.1″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_post_title author=\u00bboff\u00bb date_format=\u00bbM, j, 2013″ comments=\u00bboff\u00bb featured_image=\u00bboff\u00bb _builder_version=\u00bb4.15.1″ _module_preset=\u00bbdefault\u00bb title_text_color=\u00bb#000000″ title_font_size=\u00bb32px\u00bb meta_font_size=\u00bb14px\u00bb height=\u00bb88px\u00bb custom_margin=\u00bb||-470px|||\u00bb custom_padding=\u00bb|677px|0px|0px||\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_post_title][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=\u00bb4.15.1″ _module_preset=\u00bbdefault\u00bb custom_padding=\u00bb||0px|||\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb4_4″ _builder_version=\u00bb4.15″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_text _builder_version=\u00bb4.15.1″ _module_preset=\u00bbdefault\u00bb text_font=\u00bb|||||on|||\u00bb header_font=\u00bb|||||on|||\u00bb header_2_font=\u00bb|||||on|||\u00bb header_2_font_size=\u00bb20px\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n

Indone\u00adsia has a decent-sized and fast-growing <\/strong>OTC<\/strong>, Med\u00adical Device and Pharma mar\u00adket<\/strong> that had an esti\u00admated value of approx\u00adi\u00admately US $6.25 billion in 2012. Its large pop\u00adu\u00adla\u00adtion and rel\u00ada\u00adtively pow\u00ader\u00adful pro\u00adduc\u00adtion base give Indonesia the poten\u00adtial to become an even more lucra\u00adtive OTC, Pharma and Med\u00adical Device mar\u00adket in the future.<\/span><\/h2>\n

[\/et_pb_text][et_pb_text _builder_version=\u00bb4.15″ _module_preset=\u00bbdefault\u00bb text_font_size=\u00bb20px\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n

Indone\u00adsia has a strong generic drugs sec\u00adtor that accounts for 80% of the entire Rx mar\u00adket, of which Rx and OTC prod\u00aducts make up 70% and 30%, respec\u00adtively. In recent years, the OTC seg\u00adment has exhib\u00adited a steady growth, attribut\u00aded to the increas\u00ading amount of self-medication and acces\u00adsi\u00adbil\u00adity to more affordable drugs. Add in the sheer size of its pop\u00adu\u00adla\u00adtion, and you know: Indone\u00adsia sim\u00adply cannot be dis\u00admissed.<\/p>\n

<\/ul>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=\u00bb4.15″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb4_4″ _builder_version=\u00bb4.15″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_text _builder_version=\u00bb4.15″ _module_preset=\u00bbdefault\u00bb text_font_size=\u00bb20px\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n

\n

\n

\n

Indone\u00adsia has a strong generic drugs sec\u00adtor that accounts for 80% of the entire Rx mar\u00adket, of which Rx and OTC prod\u00aducts make up 70% and 30%, respec\u00adtively. In recent years, the OTC seg\u00adment has exhib\u00adited a steady growth, attribut\u00aded to the increas\u00ading amount of self-medication and acces\u00adsi\u00adbil\u00adity to more affordable drugs. Add in the sheer size of its pop\u00adu\u00adla\u00adtion, and you know:
Indone\u00adsia sim\u00adply cannot be dis\u00admissed.<\/p>\n

Of the 200-300 drug com\u00adpa\u00adnies that oper\u00adate in the Indone\u00adsian mar\u00adket, approx\u00adi\u00admately 40 are foreign-owned, and there are numer\u00adous food sup\u00adple\u00adment, cos\u00admetic and med\u00adical rem\u00adedy play\u00aders. Of the over\u00adall phar\u00adma\u00adceu\u00adti\u00adcal mar\u00adket in Indone\u00adsia, for\u00adeign drug-mak\u00aders con\u00adsti\u00adtute around 30%. Despite con\u00adcerns about coun\u00adter\u00adfeit\u00ading and the low efficacy of generic prod\u00aducts, the IP pro\u00adtec\u00adtion and GMP man\u00adu\u00adfac\u00adtur\u00ading stan\u00addards in Indone\u00adsia are improv\u00ading with effective national reg\u00adu\u00adla\u00adtions, for\u00adeign invest\u00adments and joint ventures with multi-national com\u00adpa\u00adnies. A lim\u00adited num\u00adber of for\u00adeign chain phar\u00adma\u00adcies can be found in most major cities in Indonesia; these include Guardian, Wat\u00adsons and Cen\u00adtury Healthcare. There are also many pri\u00advately owned local phar\u00adma\u00adcies (apotik<\/em>). One of the bet\u00adter privately owned chains is Apotik Melawai, which is based in Jakarta.<\/p>\n

The National Agency of Drug and Food Con\u00adtrol (NA-DFC) is respon\u00adsi\u00adble for the reg\u00adu\u00adla\u00adtion of phar\u00adma\u00adceu\u00adti\u00adcal prod\u00aducts and drugs in Indone\u00adsia. The pri\u00admary duties of the NA-DFC include pre-market eval\u00adu\u00ada\u00adtions, leg\u00adis\u00adla\u00adtion, reg\u00adu\u00adla\u00adtion, stan\u00addard\u00adisa\u00adtion and GMP certification of med\u00adical prod\u00aducts.<\/p>\n

A drug reg\u00adis\u00adtra\u00adtion appli\u00adca\u00adtion can only be under\u00adtaken by phar\u00adma\u00adceu\u00adti\u00adcal com\u00adpa\u00adnies located in Indone\u00adsia, and this must go through a pre-registration process, which can take up to 40 work\u00ading days. This process involves a con\u00adsul\u00adta\u00adtion on the com\u00adple\u00adtion of a reg\u00adis\u00adtra\u00adtion dossier, as well as paying doc\u00adu\u00adment and reg\u00adis\u00adtra\u00adtion fees. Companies based out\u00adside Indone\u00adsia need to find a good local part\u00adner they can trust to con\u00adduct the reg\u00adis\u00adtra\u00adtion process on their behalf.<\/p>\n<\/div>\n<\/div>\n<\/div>\n

<\/div>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"

Indone\u00adsia has a decent-sized and fast-growing OTC, Med\u00adical Device and Pharma mar\u00adket that had an esti\u00admated value of approx\u00adi\u00admately US $6.25 billion in 2012. Its large pop\u00adu\u00adla\u00adtion and rel\u00ada\u00adtively pow\u00ader\u00adful pro\u00adduc\u00adtion base give Indonesia the poten\u00adtial to become an even more lucra\u00adtive OTC, Pharma and Med\u00adical Device mar\u00adket in the future.Indone\u00adsia has a strong generic […]<\/p>\n","protected":false},"author":7,"featured_media":0,"parent":8794,"menu_order":1,"comment_status":"open","ping_status":"open","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"Indone\u00adsia has a decent-sized and fast-growing <\/strong>OTC<\/strong>, Med\u00adical Device and Pharma mar\u00adket<\/strong> that had an esti\u00admated value of approx\u00adi\u00admately US $6.25 billion in 2012. Its large pop\u00adu\u00adla\u00adtion and rel\u00ada\u00adtively pow\u00ader\u00adful pro\u00adduc\u00adtion base give Indonesia the poten\u00adtial to become an even more lucra\u00adtive OTC, Pharma and Med\u00adical Device mar\u00adket in the future.\r\n\r\nIndone\u00adsia has a strong generic drugs sec\u00adtor that accounts for 80% of the entire Rx mar\u00adket, of which Rx and OTC prod\u00aducts make up 70% and 30%, respec\u00adtively. In recent years, the OTC seg\u00adment has exhib\u00adited a steady growth, attribut\u00aded to the increas\u00ading amount of self-medication and acces\u00adsi\u00adbil\u00adity to more affordable drugs. Add in the sheer size of its pop\u00adu\u00adla\u00adtion, and you know:\r\nIndone\u00adsia sim\u00adply cannot be dis\u00admissed.\r\n\r\nOf the 200-300 drug com\u00adpa\u00adnies that oper\u00adate in the Indone\u00adsian mar\u00adket, approx\u00adi\u00admately 40 are foreign-owned, and there are numer\u00adous food sup\u00adple\u00adment, cos\u00admetic and med\u00adical rem\u00adedy play\u00aders. Of the over\u00adall phar\u00adma\u00adceu\u00adti\u00adcal mar\u00adket in Indone\u00adsia, for\u00adeign drug-mak\u00aders con\u00adsti\u00adtute around 30%. Despite con\u00adcerns about coun\u00adter\u00adfeit\u00ading and the low efficacy of generic prod\u00aducts, the IP pro\u00adtec\u00adtion and GMP man\u00adu\u00adfac\u00adtur\u00ading stan\u00addards in Indone\u00adsia are improv\u00ading with effective national reg\u00adu\u00adla\u00adtions, for\u00adeign invest\u00adments and joint ventures with multi-national com\u00adpa\u00adnies. A lim\u00adited num\u00adber of for\u00adeign chain phar\u00adma\u00adcies can be found in most major cities in Indonesia; these include Guardian, Wat\u00adsons and Cen\u00adtury Healthcare. There are also many pri\u00advately owned local phar\u00adma\u00adcies (apotik<\/em>). One of the bet\u00adter privately owned chains is Apotik Melawai, which is based in Jakarta.\r\n\r\nThe National Agency of Drug and Food Con\u00adtrol (NA-DFC) is respon\u00adsi\u00adble for the reg\u00adu\u00adla\u00adtion of phar\u00adma\u00adceu\u00adti\u00adcal prod\u00aducts and drugs in Indone\u00adsia. The pri\u00admary duties of the NA-DFC include pre-market eval\u00adu\u00ada\u00adtions, leg\u00adis\u00adla\u00adtion, reg\u00adu\u00adla\u00adtion, stan\u00addard\u00adisa\u00adtion and GMP certification of med\u00adical prod\u00aducts.\r\n\r\nA drug reg\u00adis\u00adtra\u00adtion appli\u00adca\u00adtion can only be under\u00adtaken by phar\u00adma\u00adceu\u00adti\u00adcal com\u00adpa\u00adnies located in Indone\u00adsia, and this must go through a pre-registration process, which can take up to 40 work\u00ading days. This process involves a con\u00adsul\u00adta\u00adtion on the com\u00adple\u00adtion of a reg\u00adis\u00adtra\u00adtion dossier, as well as paying doc\u00adu\u00adment and reg\u00adis\u00adtra\u00adtion fees. Companies based out\u00adside Indone\u00adsia need to find a good local part\u00adner they can trust to con\u00adduct the reg\u00adis\u00adtra\u00adtion process on their behalf.","_et_gb_content_width":"","footnotes":"","_wp_rev_ctl_limit":""},"class_list":["post-8798","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/www.chameleon-pharma.com\/es\/wp-json\/wp\/v2\/pages\/8798","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.chameleon-pharma.com\/es\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.chameleon-pharma.com\/es\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.chameleon-pharma.com\/es\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/www.chameleon-pharma.com\/es\/wp-json\/wp\/v2\/comments?post=8798"}],"version-history":[{"count":15,"href":"https:\/\/www.chameleon-pharma.com\/es\/wp-json\/wp\/v2\/pages\/8798\/revisions"}],"predecessor-version":[{"id":15250,"href":"https:\/\/www.chameleon-pharma.com\/es\/wp-json\/wp\/v2\/pages\/8798\/revisions\/15250"}],"up":[{"embeddable":true,"href":"https:\/\/www.chameleon-pharma.com\/es\/wp-json\/wp\/v2\/pages\/8794"}],"wp:attachment":[{"href":"https:\/\/www.chameleon-pharma.com\/es\/wp-json\/wp\/v2\/media?parent=8798"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}